Finally, the researchers measured the activity of genes known to FXR FXR in the knockout mice. Underneath they found low activity in which the transport of lipid components of bile involved. Once we found that the FXR – deficient animals more susceptible than normal animals getting all episodes of CGD were, we decided to explore the effects of increasing the FXR activity in a strain of mice that was known to have FXR , but that was also prone to the disease, said Mangelsdorf. We wanted to determine whether such a drug might proper balance of proper balance of bile components. .
A research team led by David J. Mangelsdorf, a Howard Hughes Medical Institute researchers at the University of Texas Southwestern Medical Center in Dallas, led published their findings 21 November 2004 version of the journal Nature Medicine. Co – authors of the paper included HHMI research associate Antonio Moschetta and Angie Bookout in Mangelsdorf lab. ‘What we saw was remarkable,’said Mangelsdorf. ‘After only five to seven days of treatment, the animals a diet that a diet that would normally produce cholesterol gallstone disease, no trace of the disease. ‘. Continue reading
Source: David Cameron Harvard Medical SchoolHarvard Medical School researchers have successfully synthesized a DNA-based memory loop in yeast cells, findings a significant a significant step forward in the emerging field of synthetic biology.
The researchers placed two of these newly synthesized, transcription factor-encoding genes in a yeast cell, and then the cell exposed to galactose . The first gene, which has been adapted for a galactose when on on a transcription factor, on on and thus activated, the second gene. Continue reading
Ethical approval by the Local Research Ethics Committee granted for the analysis of breath and urine samples from patients attended for the treatment of drug addiction. The cannabis samples are held under a Home Office Licence and have seized drug seized drug samples by working with Staffordshire Police.
courtesy of you, the entire Kaiser Daily Health Policy Report view, search the archives, or sign up for e – mail delivery at Kaiser Daily Health Policy Report published reprint of kaiser network. A free service of The Henry J. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved. Continue reading
The security Abstral was evaluated in 311 opioid-tolerant cancer patients with breakthrough pain. Two hundred and 70 of these patients were treated in multiple-dose studies. Treats the duration of therapy for patients in multiple-dose studies ranged from 1-405 days with an average duration of 131 days and with 44 patients for at least 12 months.
Transmucosal fentanyl immediate release of all products to be able to use standardized materials and a single shared implement implement the REMS .. Abstral program is only through a Risk Evaluation and Mitigation , which is available to the risk of abuse, addiction and overdose minimize. Under this program, pharmacies, distributors, and health care professionals who prescribe outpatient basis enroll in the program enroll in the program to prescribe, dispense and distribute this product. FDA has standardized key components to facilitate the REMS program to adopt a single common system. These components include the REMS document, the Patient – Prescriber Agreement and the registration form. These components can all sponsors of immediate release transmucosal fentanyl products will be used to develop individual REMS programs such as the program approved for Abstral. Continue reading